文献速递性腺与生殖内分泌肥胖与代谢综合征

对中老年男性功能性性腺功能减退症的整体管理视角

A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本文聚焦50岁及以上、常伴肥胖与共病、有雄激素缺乏临床特征且睾酮轻度降低但无下丘脑-垂体-睾丸轴解剖病理的功能性性腺功能减退症男性。文献回顾提示生活方式减重与共病优化可带来临床改善和睾酮轻度升高,症状与终末器官缺陷对靶向治疗有反应。睾酮治疗应主要考虑用于有显著雄激素缺乏临床特征且睾酮明确降低者,可与生活方式干预同时或在其失败后启动。

要点

  • 功能性性腺功能减退症在中老年肥胖伴共病男性中常见,且可能可逆。
  • 生活方式减重与共病优化可带来临床改善和睾酮轻度升高。
  • 睾酮治疗应主要考虑用于有显著雄激素缺乏特征且睾酮明确降低者。

核心结论

  • 有中等程度证据表明功能性性腺功能减退症对生活方式措施和共病优化有反应。
  • 这些干预若可实现,可能带来超出升高睾酮潜力之外的可证明健康获益。
  • 因此,应将对功能性性腺功能减退症潜在病因及症状的治疗作为睾酮治疗的初始或辅助方法。

研究设计与样本

  • 文献综述,检索范围自1970年至2016年10月。

主要发现

  • 在此类男性中,达到减重和共病优化的生活方式措施(包括停用致病药物)可带来临床改善和睾酮轻度升高。
  • 雄激素缺乏样症状和终末器官缺陷对靶向治疗(如磷酸二酯酶-5抑制剂治疗勃起功能障碍)有反应,无证据表明性腺功能减退男性对此难治。
  • 生活方式干预仍然困难,且即使成功也可能不够。

关键数值与推荐

  • 睾酮治疗应主要考虑用于有显著雄激素缺乏临床特征且睾酮水平明确降低的男性。
  • 睾酮应在生活方式措施试验的同时启动,或在此类试验失败后启动,启动前需进行个体化诊断检查、排除禁忌证并给予适当咨询。
  • 有中等程度证据表明功能性性腺功能减退症对生活方式措施和共病优化有反应。

临床怎么用

  • 对功能性性腺功能减退症潜在病因及症状的治疗应作为睾酮治疗的初始或辅助方法。
  • 睾酮治疗应主要考虑用于有显著雄激素缺乏临床特征且睾酮水平明确降低的男性。
  • 睾酮应在生活方式措施试验的同时启动,或在此类试验失败后启动,启动前需进行个体化诊断检查、排除禁忌证并给予适当咨询。

局限性

  • 缺乏决定性随机对照试验。
  • 生活方式干预仍然困难,且即使成功也可能不够。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Middle-aged and older men (≥50 years), especially those who are obese and suffer from comorbidities, not uncommonly present with clinical features consistent with androgen deficiency and modestly reduced testosterone levels. Commonly, such men do not demonstrate anatomical hypothalamic-pituitary-testicular axis pathology but have functional hypogonadism that is potentially reversible. EVIDENCE ACQUISITION: Literature review from 1970 to October 2016. EVIDENCE SYNTHESIS: Although definitive randomized controlled trials are lacking, evidence suggests that in such men, lifestyle measures to achieve weight loss and optimization of comorbidities, including discontinuation of offending medications, lead to clinical improvement and a modest increase in testosterone. Also, androgen deficiency-like symptoms and end-organ deficits respond to targeted treatments (such as phosphodiesterase-5 inhibitors for erectile dysfunction) without evidence that hypogonadal men are refractory. Unfortunately, lifestyle interventions remain difficult and may be insufficient even if successful. Testosterone therapy should be considered primarily for men who have significant clinical features of androgen deficiency and unequivocally low testosterone levels. Testosterone should be initiated either concomitantly with a trial of lifestyle measures, or after such a trial fails, after a tailored diagnostic work-up, exclusion of contraindications, and appropriate counseling. CONCLUSIONS: There is modest evidence that functional hypogonadism responds to lifestyle measures and optimization of comorbidities. If achievable, these interventions may have demonstrable health benefits beyond the potential for increasing testosterone levels. Therefore, treatment of underlying causes of functional hypogonadism and of symptoms should be used either as an initial or adjunctive approach to testosterone therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017. PMID: 28359097. doi:10.1210/jc.2016-3580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。